Global Respiratory Virus Infection Drugs Market (2020 to 2030)
06 Jul 2021
Dublin, July 06, 2021 (GLOBE NEWSWIRE) -- The "Respiratory Virus Infection Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 - 2030" report has been added to ResearchAndMarkets.com's offering. The publisher's report on the global respiratory virus infection drugs market studies past as well as current growth trends and opportunities to gain valuable insights of these indicators of the market during the forecast period from 2020 to 2030. The report provides revenue of the global respiratory virus infection drugs market for the period 2018-2030, considering 2019 as the base year and 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global respiratory virus infection drugs market during the forecast period.The report has been prepared after primary and secondary researches. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the global respiratory virus infection drugs market.Secondary research also included Internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various phenomenon in the global respiratory virus infection drugs market.The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global respiratory virus infection drugs market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global respiratory virus infection drugs market.The report delves into the competitive landscape of the global respiratory virus infection drugs market. Key players operating in the global respiratory virus infection drugs market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global respiratory virus infection drugs market that have been profiled in this report.Key Questions Answered in Respiratory Virus Infection Drugs Market Report
Key Topics Covered: 1. Preface2. Assumptions and Research Methodology3. Executive Summary: Global Respiratory Virus Infection Drugs Market4. Market Overview4.1. Introduction4.1.1. Drug Type Definition4.1.2. Industry Evolution / Developments4.2. Overview4.3. Market Dynamics4.3.1. Drivers4.3.2. Restraints4.3.3. Opportunities4.4. Global Respiratory Virus Infection Drugs Market Analysis and Forecast, 2018-20305. Key Insights5.1. Healthcare Industry Overview5.2. Pipeline Analysis (asthma and COPD)5.3. Regulatory Scenario 5.4. Disease Prevalence Rate in Key Countries5.5. Key Market Events5.6. COVID-19 Pandemic Impact on Industry6. Global Respiratory Virus Infection Drugs Market Analysis and Forecast, by Drug Type6.1. Introduction & Definition6.2. Key Findings / Developments6.3. Market Value Forecast, by Drug Type, 2018-20306.3.1. Antibiotics6.3.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)6.3.3. Cough Suppressants6.3.4. Nasal Decongestants6.3.5. Others6.4. Market Attractiveness Analysis, by Drug Type7. Global Respiratory Virus Infection Drugs Market Analysis and Forecast, by Infection Type7.1. Introduction & Definition7.2. Key Findings / Developments7.3. Market Value Forecast, by Infection Type, 2018-20307.3.1. Respiratory Syncytial Virus (RSV) Infection7.3.2. Influenza Virus Infection7.3.3. Parainfluenza Virus Infection7.3.4. Adenovirus Infection7.3.5. Rhinovirus Infection7.3.6. Others7.4. Market Attractiveness Analysis, by Infection Type8. Global Respiratory Virus Infection Drugs Market Analysis and Forecast, by Route of Administration8.1. Introduction & Definition8.2. Key Findings / Developments8.3. Market Value Forecast, by Route of Administration, 2018-20308.3.1. Oral8.3.2. Parenteral8.4. Market Attractiveness Analysis, by Route of Administration9. Global Respiratory Virus Infection Drugs Market Analysis and Forecast, by Mode of Purchase9.1. Introduction & Definition9.2. Key Findings / Developments9.3. Market Value Forecast, by Mode of Purchase, 2018-20309.3.1. Prescription-based Drugs9.3.2. Over-the-Counter Drugs9.4. Market Attractiveness Analysis, by Mode of Purchase10. Global Respiratory Virus Infection Drugs Market Analysis and Forecast, by Distribution Channel10.1. Introduction & Definition10.2. Key Findings / Developments10.3. Market Value Forecast, by Distribution Channel, 2018-203010.3.1. Hospital Pharmacies10.3.2. Drug Stores10.3.3. Retail Pharmacies10.3.4. Clinics10.3.5. Others10.4. Market Attractiveness Analysis, by Distribution Channel11. Global Respiratory Virus Infection Drugs Market Analysis and Forecast, by Region11.1. Key Findings11.2. Market Value Forecast, by Region11.2.1. North America 11.2.2. Europe 11.2.3. Asia Pacific 11.2.4. Latin America 11.2.5. Middle East & Africa 11.3. Market Attractiveness Analysis, by Country/Region
12. North America Respiratory Virus Infection Drugs Market Analysis and Forecast
13. Europe Respiratory Virus Infection Drugs Market Analysis and Forecast
14. Asia Pacific Respiratory Virus Infection Drugs Market Analysis and Forecast
15. Latin America Respiratory Virus Infection Drugs Market Analysis and Forecast
16. Middle East & Africa Respiratory Virus Infection Drugs Market Analysis and Forecast
17. Competition Landscape17.1. Market Player - Competition Matrix (by tier and size of companies)17.2. Market Share Analysis/Ranking, by Company, 201917.3. Company Profiles17.3.1. GlaxoSmithKline plc 17.3.1.1. Company Overview17.3.1.2. Company Financials17.3.1.3. Growth Strategies17.3.1.4. SWOT Analysis17.3.2. Merck & Co., Inc. 17.3.2.1. Company Overview17.3.2.2. Company Financials17.3.2.3. Growth Strategies17.3.2.4. SWOT Analysis17.3.3. AstraZeneca17.3.3.1. Company Overview17.3.3.2. Company Financials17.3.3.3. Growth Strategies17.3.3.4. SWOT Analysis17.3.4. Boehringer Ingelheim International GmbH 17.3.4.1. Company Overview17.3.4.2. Company Financials17.3.4.3. Growth Strategies17.3.4.4. SWOT Analysis17.3.5. F. Hoffmann-La Roche Ltd. 17.3.5.1. Company Overview17.3.5.2. Company Financials17.3.5.3. Growth Strategies17.3.5.4. SWOT Analysis17.3.6. Teva Pharmaceutical Industries Ltd. 17.3.6.1. Company Overview17.3.6.2. Company Financials17.3.6.3. Growth Strategies17.3.6.4. SWOT Analysis17.3.7. Sanofi17.3.7.1. Company Overview17.3.7.2. Company Financials17.3.7.3. Growth Strategies17.3.7.4. SWOT Analysis17.3.8. Cipla, Inc. 17.3.8.1. Company Overview17.3.8.2. Company Financials17.3.8.3. Growth Strategies17.3.8.4. SWOT Analysis17.3.9. CHIESI Farmaceutici S.p.A. 17.3.9.1. Company Overview17.3.9.2. Company Financials17.3.9.3. Growth Strategies17.3.9.4. SWOT Analysis17.3.10. Orion Corporation17.3.10.1. Company Overview17.3.10.2. Growth Strategies17.3.10.3. SWOT AnalysisFor more information about this report visit
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.